Press Releases

INOVIO Reports Inducement Grants Under Inducement Plan

Posted on September 1, 2022

INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Posted on August 30, 2022

INOVIO Reports Financial Results and Highlights for the Second Quarter 2022

Posted on August 9, 2022

INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022

Posted on July 26, 2022

INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients

Posted on July 19, 2022

INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Posted on July 1, 2022

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

Posted on June 27, 2022

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022

Posted on May 27, 2022

INOVIO to Present at Jefferies 2022 Healthcare Conference

Posted on May 23, 2022

INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer

Posted on May 10, 2022

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.